Novartis AG ADR (NVS)vsXWELL Inc. (XWEL)
NVS
Novartis AG ADR
$138.70
+1.60%
HEALTHCARE · Cap: $260.70B
XWEL
XWELL Inc.
$0.91
0.00%
HEALTHCARE · Cap: $8.93M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 200356% more annual revenue ($56.69B vs $28.28M). NVS leads profitability with a 22.5% profit margin vs -82.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
XWEL
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$138.70
$45.41 premium
Margin of Safety
+57.2%
Fair Value
$0.92
Current Price
$0.91
$0.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Trading at 18.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : XWEL
The strongest argument for XWEL centers on Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : XWEL
The primary concerns for XWEL are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a value stock while XWEL is a turnaround play — different risk/reward profiles.
XWEL carries more volatility with a beta of 1.01 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 22/100), backed by strong 22.5% margins. XWEL offers better value entry with a 57.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →XWELL Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
XWELL Inc., a health and wellness services company, provides spa services at airports. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?